1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Engineered TCR (T-Cell Receptor) Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Engineered TCR (T-Cell Receptor) Therapy Market, by Therapy Type / TCR Design
8.1.1. Natural TCR Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Affinity-Enhanced TCR Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Gene-Edited / Non-Viral TCR Therapy
8.1.3.1. Market Revenue and Forecast
9.1. Engineered TCR (T-Cell Receptor) Therapy Market, by Delivery Method
9.1.1. Viral Vector-Based TCR Therapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Non-Viral Vector / Gene Editing-Based Therapy
9.1.2.1. Market Revenue and Forecast
10.1. Engineered TCR (T-Cell Receptor) Therapy Market, by Indication / Cancer Type
10.1.1. Solid Tumors (melanoma, lung cancer, colorectal cancer, etc.)
10.1.1.1. Market Revenue and Forecast
10.1.2. Hematologic Malignancies (leukemia, lymphoma, myeloma)
10.1.2.1. Market Revenue and Forecast
10.1.3. Infectious Diseases (emerging clinical research)
10.1.3.1. Market Revenue and Forecast
11.1. Engineered TCR (T-Cell Receptor) Therapy Market, by End-User
11.1.1. Pharmaceutical & Biotechnology Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Development and Manufacturing Organizations (CDMOs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.1.2. Market Revenue and Forecast, by Delivery Method
12.1.3. Market Revenue and Forecast, by Indication / Cancer Type
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.1.5.2. Market Revenue and Forecast, by Delivery Method
12.1.5.3. Market Revenue and Forecast, by Indication / Cancer Type
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.1.6.2. Market Revenue and Forecast, by Delivery Method
12.1.6.3. Market Revenue and Forecast, by Indication / Cancer Type
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.2.2. Market Revenue and Forecast, by Delivery Method
12.2.3. Market Revenue and Forecast, by Indication / Cancer Type
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.2.5.2. Market Revenue and Forecast, by Delivery Method
12.2.5.3. Market Revenue and Forecast, by Indication / Cancer Type
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.2.6.2. Market Revenue and Forecast, by Delivery Method
12.2.6.3. Market Revenue and Forecast, by Indication / Cancer Type
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.2.7.2. Market Revenue and Forecast, by Delivery Method
12.2.7.3. Market Revenue and Forecast, by Indication / Cancer Type
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.2.8.2. Market Revenue and Forecast, by Delivery Method
12.2.8.3. Market Revenue and Forecast, by Indication / Cancer Type
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.3.2. Market Revenue and Forecast, by Delivery Method
12.3.3. Market Revenue and Forecast, by Indication / Cancer Type
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.3.5.2. Market Revenue and Forecast, by Delivery Method
12.3.5.3. Market Revenue and Forecast, by Indication / Cancer Type
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.3.6.2. Market Revenue and Forecast, by Delivery Method
12.3.6.3. Market Revenue and Forecast, by Indication / Cancer Type
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.3.7.2. Market Revenue and Forecast, by Delivery Method
12.3.7.3. Market Revenue and Forecast, by Indication / Cancer Type
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.3.8.2. Market Revenue and Forecast, by Delivery Method
12.3.8.3. Market Revenue and Forecast, by Indication / Cancer Type
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.4.2. Market Revenue and Forecast, by Delivery Method
12.4.3. Market Revenue and Forecast, by Indication / Cancer Type
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.4.5.2. Market Revenue and Forecast, by Delivery Method
12.4.5.3. Market Revenue and Forecast, by Indication / Cancer Type
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.4.6.2. Market Revenue and Forecast, by Delivery Method
12.4.6.3. Market Revenue and Forecast, by Indication / Cancer Type
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.4.7.2. Market Revenue and Forecast, by Delivery Method
12.4.7.3. Market Revenue and Forecast, by Indication / Cancer Type
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.4.8.2. Market Revenue and Forecast, by Delivery Method
12.4.8.3. Market Revenue and Forecast, by Indication / Cancer Type
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.5.2. Market Revenue and Forecast, by Delivery Method
12.5.3. Market Revenue and Forecast, by Indication / Cancer Type
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.5.5.2. Market Revenue and Forecast, by Delivery Method
12.5.5.3. Market Revenue and Forecast, by Indication / Cancer Type
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type / TCR Design
12.5.6.2. Market Revenue and Forecast, by Delivery Method
12.5.6.3. Market Revenue and Forecast, by Indication / Cancer Type
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. Lion TCR Pte Ltd.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. TCRCure Biopharma Corp.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Asher Biotherapeutics Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Be Biopharma Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. China Immunotech Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Immatics N.V.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Adaptimmune Therapeutics plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Atara Biotherapeutics Inc
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Alaunos Therapeutics Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Immunocore Limited
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
